Atmaca Murad, Tezcan Ertan, Kuloglu Murat, Ustundag Bilal, Kirtas Ozlem
Department of Psychiatry, Firat University, School of Medicine, Elazig, Turkey.
Psychiatry Clin Neurosci. 2005 Dec;59(6):652-6. doi: 10.1111/j.1440-1819.2005.01432.x.
It has been suggested that the extract of gingko biloba (EGb) may enhance the efficiency of the classic antipsychotic haloperidol in patients with chronic schizophrenia, especially on positive symptoms, and reduce serum superoxide dismutase (SOD) levels. Therefore, we decided to evaluate the therapeutic effect of EGb and to examine the effect of it on the levels of antioxidant enzymes in schizophrenic patients on olanzapine treatment. We hypothesized that EGb would have the beneficial effects on schizophrenic symptoms and might cause reductions in antioxidant enzymes. The subjects were randomly assigned to the two groups: olanzapine plus EGb (group I) (n=15) and olanzapine alone (group II) (n=14). The patients were evaluated at baseline and at week 8 with respect to the Positive and Negative Syndrome Scale (PANSS), serum SOD, catalase (CAT), and glutathion peroxidase (GPX) levels. At baseline, no statistically significant difference regarding the mean total PANSS scores between treatment groups was found. At the evaluation of week 8, a significant difference in mean Scale for the Assessment of Postive Symptoms (SAPS) scores but not in Scale for the Assessment of Negative Symptoms scores between groups was found. Total patients had statistically significant higher serum SOD, CAT and GPX levels compared to control groups at baseline. At 8 weeks, there were significant differences in the mean decrease in SOD and CAT levels but not in GPX levels between treatment groups. The changes in SOD and CAT levels were correlated with the change in SAPS in group I, but not in the group II. The present study supported the findings of the previous study demonstrating that EGb might enhance the efficiency of antipsychotic in patients with schizophrenia, particularly on positive symptoms of the disorder.
有人提出，银杏叶提取物（EGb）可能会提高经典抗精神病药物氟哌啶醇对慢性精神分裂症患者的疗效，尤其是对阳性症状的疗效，并降低血清超氧化物歧化酶（SOD）水平。因此，我们决定评估EGb的治疗效果，并研究其对接受奥氮平治疗的精神分裂症患者抗氧化酶水平的影响。我们假设EGb对精神分裂症症状有有益作用，并且可能会导致抗氧化酶水平降低。研究对象被随机分为两组：奥氮平加EGb组（I组）（n = 15）和单独使用奥氮平组（II组）（n = 14）。在基线和第8周时，对患者进行阳性和阴性症状量表（PANSS）、血清SOD、过氧化氢酶（CAT）和谷胱甘肽过氧化物酶（GPX）水平的评估。在基线时，各治疗组之间的平均PANSS总分无统计学显著差异。在第8周评估时，发现两组之间阳性症状评估量表（SAPS）得分有显著差异，但阴性症状评估量表得分无显著差异。与对照组相比，所有患者在基线时血清SOD、CAT和GPX水平均有统计学显著升高。在第8周时，治疗组之间SOD和CAT水平的平均降低幅度有显著差异，但GPX水平无显著差异。I组中SOD和CAT水平的变化与SAPS的变化相关，但II组中不相关。本研究支持了先前的研究结果，表明EGb可能会提高抗精神病药物对精神分裂症患者的疗效，尤其是对该疾病的阳性症状。
